Retatrutide vs tirzepatide vs semaglutide
The three most-studied incretin peptides, side by side: what each one targets, its molecular data, how long it lasts and how to store it.
In short: semaglutide activates one receptor (GLP-1), tirzepatide two (GLP-1 and GIP) and retatrutide three (GLP-1, GIP and glucagon). All three are once-weekly, albumin-binding peptides with half-lives of roughly 5–7 days. Tirzepatide and semaglutide are approved medicines; retatrutide is still in phase 3 trials.
| Retatrutide | Tirzepatide | Semaglutide | |
|---|---|---|---|
| Receptors targeted | GLP-1, GIP and glucagon (triple agonist) | GLP-1 and GIP (dual agonist) | GLP-1 only |
| Research name at GLP-123 | GLP-3 RT | GLP-2 TZ | GLP-1 SG |
| Peptide length | 39 amino acids | 39 amino acids | 31 amino acids |
| Molecular formula | C221H342N46O68 | C225H348N48O68 | C187H291N45O59 |
| Molecular weight | ≈ 4,731 g/mol | ≈ 4,813 g/mol | ≈ 4,114 g/mol |
| CAS number | 2381089-83-2 | 2023788-19-2 | 910463-68-2 |
| Half-life extension | Fatty diacid (C20) side chain, albumin binding | Fatty diacid (C20) side chain, albumin binding | Fatty diacid (C18) side chain, albumin binding |
| Reported elimination half-life | ≈ 6 days | ≈ 5 days | ≈ 7 days |
| Regulatory status (2026) | Investigational, phase 3 (TRIUMPH program) | Approved (Mounjaro 2022, Zepbound 2023) | Approved (Ozempic 2017, Wegovy 2021, oral Rybelsus 2019) |
| Landmark trial | Phase 2 obesity trial (NEJM 2023) | SURMOUNT-1 (NEJM 2022) | STEP 1 (NEJM 2021) |
| Lyophilized storage | −20 °C long term, protected from light | −20 °C long term, protected from light | −20 °C long term, protected from light |
| After reconstitution | 2–8 °C, use within the window your protocol validates | 2–8 °C, use within the window your protocol validates | 2–8 °C, use within the window your protocol validates |
| GLP-123 batches tested | 6 batches, avg purity 99.68% | 12 batches, avg purity 99.71% | 3 batches, avg purity 99.87% |
Questions researchers ask
What is the main difference between retatrutide, tirzepatide and semaglutide?
The number of receptors each one activates. Semaglutide activates only the GLP-1 receptor. Tirzepatide activates GLP-1 and GIP receptors. Retatrutide adds the glucagon receptor, making it a triple agonist.
Which has the longest half-life?
Semaglutide, at about 7 days, followed by retatrutide (about 6 days) and tirzepatide (about 5 days). All three use a fatty-acid side chain that binds albumin to slow clearance.
Is retatrutide approved?
No. As of 2026 retatrutide is investigational and in phase 3 trials. Tirzepatide and semaglutide are approved medicines. Research-grade versions of all three are for laboratory use only.
How should these peptides be stored for research?
Lyophilized powder is typically kept at −20 °C, protected from light. Once reconstituted, keep vials at 2–8 °C and use them within the stability window your protocol has validated.
Sources
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023;389:514-526.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002.
- PubChem compound records: retatrutide, tirzepatide, semaglutide (formula, molecular weight, CAS).
Half-life values are reported human pharmacokinetic figures from published studies, given for context. Research-grade peptides from GLP-123 are for laboratory use only.